Randomised study to compare aspirin versus hydroxyurea/aspirin in 'intermediate risk' primary thrombocythaemia (PT) and hydroxyurea/aspirin versus anagrelide/aspirin in 'high risk' primary thrombocythaemia
Completed
- Conditions
- eukaemiaCancerLeukaemia
- Registration Number
- ISRCTN72251782
- Lead Sponsor
- Medical Research Council (MRC) (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 1600
Inclusion Criteria
All patients over 18 years of age meeting diagnostic criteria of PT
Exclusion Criteria
Severe heart disease excludes patients from the 'high risk' study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Vascular occlusion, haemorrhagic events, death, drug side-effects, transformation to acute leukaemia or myelofibrosis
- Secondary Outcome Measures
Name Time Method ot provided at time of registration